Arietis Corp.is a Boston-based biotechnology company focused on the discovery and development of novel antimicrobial agents.  Our drug discovery pipelines include the identification of narrow spectrum antibiotics specifically targeting H. pylori and C. difficile, the causes of ulcers and antibiotic associated diarrhea, respectively. We also have broad spectrum drug discovery platforms focused on sterilizing antifungals and a new class of antibacterial agents called “prodrug antibiotics”. Founded in 2006, the Arietis approach and technology are totally novel and will bridge the current vacuum in antimicrobial therapeutics. Arietis has forged productive alliances and partnerships within the biotechnology community that advance our capacity to develop effective drug products. We are committed to providing innovative solutions to the problem of persistent infections, thereby decreasing the burden on health systems worldwide.

The company was created based on technology invented by its founder, Professor Kim Lewis, Director of the Antimicrobial Center at Northeastern University, for which the company has obtained exclusive, world-wide licenses. Arietis is led by Dr. Thomas A. Dahl, CEO, an experienced business executive and drug developer.